Business & Finance
Omnicell announces record revenue rise of 3.3 % for Q3 2017
27 October 2017 -

Medication company Omnicell Inc (NASDAQ:OMCL) stated on Thursday its GAAP net income of USD6.2m (USD0.16 per diluted share) for its third quarter ended 30 September 2017.

This marks a growth when compared with GAAP net income of USD0.8m (USD0.02 per diluted share) for the second quarter of 2017 and GAAP net income of USD2.0m (USD0.05 per diluted share) for the third quarter of 2016, respectively.

GAAP revenue of USD186.8m were collected for the third quarter of 2017, a rise of USD5.9m (3.3%) over the second quarter of 2017 and USD10.1m (5.7%) from the third quarter of 2016, respectively.

In Q4 2017, the company anticipates both GAAP and non-GAAP revenue in the USD201m and USD207m range and non-GAAP earnings in USD0.49 and USD0.55 per share range. In 2017, its expects both GAAP and non-GAAP revenue in the USD720m and USD726m range and non-GAAP earnings in USD1.27 and USD1.33 per share.

Login
Username:

Password: